NY Profs say a combination of four targeted therapies could eventually replace chemotherapy for Herceptin receptor-positive breast cancer.
The post Bulletin: Encouraging early results for HR+/HER2+ breast cancer chemo-free treatment appeared first on Medical News Bulletin.
Fasting fewer than 8 hours or more than 12 hours before a routine blood test did not significantly impact the results, new observational data in JAMA Internal Medicine show.
The practice of fasting before blood tests is intended to reduce variability in measurements, but recommendations for fasting durations are inconsistent, according to Sunghwan Shin, MD, PhD, from University of Ulsan College of Medicine in Seoul, Korea, and colleagues.
They added that evidence needed to determine optimal fasting time is limited by multiple factors, including:
The researchers aimed to address these gaps by
The FDA expanded the approval of pirtobrutinib to include initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.
Pirtobrutinib (Jaypirca, Eli Lilly & Co.) — a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor — already had been approved for patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) who already received a BTK inhibitor. It also is approved for certain patients with relapsed or refractory mantle cell lymphoma.
The indication for treatment-naive CLL/SLL is based on results of the
SAN DIEGO — Less than half of families who own firearms and have young children reported storing them securely, according to survey results presented at the AAP National Conference & Exhibition.
Firearm injuries are the leading cause of death for children in the United States, and according to the AAP, one-third of children live in a home with firearms. Additionally, unintentional firearm injuries among children younger than 5 years are rising, Alison L. Miller, PhD, associate chair and professor of health behavior and health equity at the University of Michigan School of Public Health,
Merck has decided to discontinue production of a combination antibiotic used in hospitals to target life-threatening infections resistant to other medications.
The drug company told Healio the decision to pull Recarbrio off the U.S. market was part of an “ongoing portfolio review” and not based on product safety or quality issues. It expected the remaining inventory to be depleted by the end of last month.
“We understand that Recarbrio has been an important option for certain patients,” Merck said in an email. “Alternative therapeutic options remain available for the approved indications.”
ANAHEIM, Calif. — Even though studies have linked GLP-1s to development of nonarteritic anterior ischemic neuropathy, the risk is not great enough to warrant stopping the medication, according to a speaker at Academy 2026.
“We need to follow the data, not so much what is being reported in the media,” Leonard V. Messner, OD, FAAO, professor of optometry at Illinois College of Optometry, said. “The best approach is vigilance, not a knee-jerk response.”
He emphasized that “the overall absolute risk remains very, very low.”
In the U.S., lawsuits are underway against GLP-1 manufacturers Novo Nordisk
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
This month we are discussing the management of severe neurotrophic keratitis (NK), an uncommon but severe degenerative disease of the cornea characterized by compromised corneal sensory innervation. Oxervate (cenegermin-bkbj, Dompé), a recombinant human nerve growth factor for topical administration, has been a game changer in the treatment of patients with NK. It is FDA approved but requires a
ANAHEIM, Calif. — Treating dry eye disease with both Xiidra and Miebo led to significant improvements in signs and symptoms, with most patients still using both drops months later, according to data presented at Academy 2026.
The finding comes shortly after Bausch + Lomb announced that an eye drop combining Xiidra (lifitegrast ophthalmic solution 5%) and Miebo (perfluorohexyloctane ophthalmic solution) would be evaluated in a phase 3 study.
“As a clinician treating many patients with moderate to severe dry eye disease, I regularly incorporate pharmaceutical treatments with different mechanisms
People who experienced transient ischemic attack had a higher risk for developing dementia than those who did not have one, and dementia rates in these patients were three times higher than stroke rates over the long term, according to researchers.
The results indicate that long-term follow-up for patients who experience a transient ischemic attack (TIA) should take cognitive and brain health into consideration, along with stroke prevention, said Raed A. Joundi, MD, DPhil, assistant professor in the department of medicine, division of neurology, at McMaster University.
“It would be important to
The AMA is urging the Federal Aviation Administration to rethink its proposed changes to requirements for emergency medical kits on commercial airlines.
Allowing each airline to determine its own medical supplies could compromise the safety of passengers during an in-flight emergency, according to an AMA press release.
In a comment letter to Federal Aviation Administration Administrator Bryan Bedford, AMA’s CEO and Executive Vice President John Whyte, MD, MPH, strongly supported updating the 2-decade-old onboard medical kit requirements but opposed the proposal to entirely eliminate federal